0000000000158327

AUTHOR

Klaus G. Griewank

0000-0003-3899-9449

showing 7 related works from this author

Acquired IFNγ resistance impairs anti-tumor immunity and gives rise to T-cell-resistant melanoma lesions

2016

Melanoma treatment has been revolutionized by antibody-based immunotherapies. IFNγ secretion by CD8+ T cells is critical for therapy efficacy having anti-proliferative and pro-apoptotic effects on tumour cells. Our study demonstrates a genetic evolution of IFNγ resistance in different melanoma patient models. Chromosomal alterations and subsequent inactivating mutations in genes of the IFNγ signalling cascade, most often JAK1 or JAK2, protect melanoma cells from anti-tumour IFNγ activity. JAK1/2 mutants further evolve into T-cell-resistant HLA class I-negative lesions with genes involved in antigen presentation silenced and no longer inducible by IFNγ. Allelic JAK1/2 losses predisposing to …

Patient-Specific Modeling0301 basic medicineSkin NeoplasmsBiopsyT-LymphocytesDNA Mutational AnalysisDatasets as TopicGeneral Physics and AstronomyAntineoplastic Agents ImmunologicalMutation RatePrecision MedicineMelanomaSkinAntigen PresentationMultidisciplinarybiologyMelanomaQfood and beverages3. Good healthTreatment Outcomemedicine.anatomical_structureImmunotherapyAntibodySignal TransductionScienceT cellAntigen presentationHuman leukocyte antigenArticleGeneral Biochemistry Genetics and Molecular BiologyInterferon-gamma03 medical and health sciencesAntigenAntigens NeoplasmCell Line TumormedicineHumansWhole Genome SequencingHistocompatibility Antigens Class IJanus Kinase 1General ChemistryJanus Kinase 2medicine.disease030104 developmental biologyImmunoeditingDrug Resistance NeoplasmMutationImmunologybiology.proteinTumor EscapeCD8Nature Communications
researchProduct

Differential influence of vemurafenib and dabrafenib on patient lymphocytes despite similar clinical efficacy in melanoma

2014

Background: Since the majority of melanomas eventually become resistant and progress, combining selective BRAF inhibitors (BRAFi) with immunotherapies has been proposed to achieve more durable treatment responses. Here, we explored the impact of selective BRAFi on the hosts’ immune system. Patients and methods: Clinical data, whole blood counts (WBC) and serum lactate dehydrogenase (LDH) of 277 vemurafenib- and 65 dabrafenib-treated melanoma patients were evaluated. The frequency and phenotype of lymphocyte subpopulations were determined by flow cytometry while T cell cytokine secretion was measured by multiplex assays. Results: Progression-free survival (PFS) as well as overall survival (O…

lymphocytesmedicine.medical_treatmentT cellLymphocyte2720 HematologyMedizinT cells610 Medicine & healthPharmacology142-005 142-005melanomamedicineInterleukin 9dabrafenibVemurafenibtreatmentbusiness.industryMelanomaDabrafenibOriginal ArticlesHematologyImmunotherapymedicine.diseasemedicine.anatomical_structureOncology2730 OncologyvemurafenibCytokine secretionbusinessmedicine.drug
researchProduct

Miltefosine Efficiently Eliminates Leishmania major Amastigotes from Infected Murine Dendritic Cells without Altering Their Immune Functions▿

2009

ABSTRACT As a treatment for leishmaniasis, miltefosine exerts direct toxic effects on the parasites. Miltefosine also modulates immune cells such as macrophages, leading to parasite elimination via oxidative radicals. Dendritic cells (DC) are critical for initiation of protective immunity against Leishmania through induction of Th1 immunity via interleukin 12 (IL-12). Here, we investigated the effects of miltefosine on DC in Leishmania major infections. When cocultured with miltefosine for 4 days, the majority of in vitro -infected DC were free of parasites. Miltefosine treatment did not influence DC maturation (upregulation of major histocompatibility complex II [MHC II] or costimulatory m…

CD4-Positive T-LymphocytesPhosphorylcholineAntigen presentationAntiprotozoal AgentsLeishmaniasis CutaneousApoptosisBiologyCD8-Positive T-LymphocytesMicrobiologyMiceImmune systemmedicineAnimalsPharmacology (medical)Leishmania majorAntigen-presenting cellMechanisms of Action: Physiological EffectsCells CulturedCell ProliferationLeishmania majorPharmacologyMiltefosineDendritic cellDendritic Cellsbiology.organism_classificationLeishmaniaMice Inbred C57BLInfectious DiseasesImmunologyInterleukin 12medicine.drug
researchProduct

Genetic evolution of T-cell resistance in the course of melanoma progression

2014

Abstract Purpose: CD8+ T lymphocytes can kill autologous melanoma cells, but their activity is impaired when poorly immunogenic tumor phenotypes evolve in the course of disease progression. Here, we analyzed three consecutive melanoma lesions obtained within one year of developing stage IV disease for their recognition by autologous T cells. Experimental Design: One skin (Ma-Mel-48a) and two lymph node (Ma-Mel-48b, Ma-Mel-48c) metastases were analyzed for T-cell infiltration. Melanoma cell lines established from the respective lesions were characterized, determining the T-cell–stimulatory capacity, expression of surface molecules involved in T-cell activation, and specific genetic alteratio…

Cancer ResearchB7 Antigensmedicine.medical_treatmentMedizinGene ExpressionT-Lymphocyte Subsetshemic and lymphatic diseasesCluster AnalysisLymphocytesNeoplasm MetastasisLymph nodeMelanomaTumorImmunogenicityMelanomaSingle Nucleotidemedicine.anatomical_structurePhenotypeButorphanolOncologyDisease ProgressionCytokinesEvolutionT cellHuman leukocyte antigenBiologyPolymorphism Single NucleotideArticleCell LineEvolution MolecularLymphocytes Tumor-InfiltratingCell Line TumormedicineHumansGenetic Predisposition to DiseaseTumor-InfiltratingAllelePolymorphismneoplasmsAllelesNeoplasm StagingHistocompatibility Antigens Class IMolecularImmunotherapymedicine.diseaseAlleles; B7 Antigens; Butorphanol; Cell Line Tumor; Cluster Analysis; Cytokines; Disease Progression; Gene Expression; Genetic Predisposition to Disease; Histocompatibility Antigens Class I; Humans; Lymphocytes Tumor-Infiltrating; Melanoma; Mutation; Neoplasm Metastasis; Neoplasm Staging; Phenotype; Polymorphism Single Nucleotide; T-Lymphocyte Subsets; beta 2-Microglobulin; Evolution Molecular; Oncology; Cancer ResearchImmunologyMutationbeta 2-MicroglobulinCD8
researchProduct

Immune Modulating Effects of NKT Cells in a Physiologically Low Dose Leishmania major Infection Model after αGalCer Analog PBS57 Stimulation

2014

Leishmaniasis is a parasitic infection affecting ∼12 million people worldwide, mostly in developing countries. Treatment options are limited and no effective vaccines exist to date. Natural Killer T (NKT) cells are a conserved innate-like lymphocyte population with immunomodulating effects in various settings. A number of reports state a role of NKT cells in different models of Leishmania infection. Here, we investigated the effect of NKT cells in a physiologically relevant, intradermal low dose infection model. After inoculation of 103 infectious-stage L. major, comparable numbers of skin-immigrating NKT cells in both susceptible BALB/c mice and resistant C57BL/6 mice were noted. Compared …

medicine.medical_treatmentLymphocyteMedizinPathogenesisNK cellsProtozoologyPathology and Laboratory MedicineCellular typesMedicine and Health SciencesLymphoid OrgansLeishmania majorImmune ResponseLeishmania majorSkinProtozoansMice Inbred BALB Ceducation.field_of_studybiologylcsh:Public aspects of medicineNatural killer T cellInfectious Diseasesmedicine.anatomical_structureCytokineMedical MicrobiologyHost-Pathogen InteractionsWhite blood cellsCytokinesAnatomyResearch ArticleCell biologyBlood cellslcsh:Arctic medicine. Tropical medicinelcsh:RC955-962Immune CellsImmunologyPopulationT cellsLeishmaniasis CutaneousGalactosylceramidesSpleenImmunopathologyMicrobiologyLymphatic SystemImmunomodulationImmune ActivationImmune systemImmunityMicrobial ControlmedicineAnimalsImmunologic FactorseducationImmunity to InfectionsMicrobial PathogensBiology and life sciencesImmunityOrganismsPublic Health Environmental and Occupational HealthImmunoregulationlcsh:RA1-1270Molecular Developmentbiology.organism_classificationAcquired Immune SystemParasitic ProtozoansMice Inbred C57BLDisease Models AnimalAnimal cellsImmune SystemImmunologyNatural Killer T-CellsClinical ImmunologyParasitologyDevelopmental Biology
researchProduct

Melanoma Lesions Independently Acquire T-cell Resistance during Metastatic Latency

2016

Abstract Melanoma often recurs after a latency period of several years, presenting a T cell–edited phenotype that reflects a role for CD8+ T cells in maintaining metastatic latency. Here, we report an investigation of a patient with multiple recurrent lesions, where poorly immunogenic melanoma phenotypes were found to evolve in the presence of autologous tumor antigen–specific CD8+ T cells. Melanoma cells from two of three late recurrent metastases, developing within a 6-year latency period, lacked HLA class I expression. CD8+ T cell–resistant, HLA class I–negative tumor cells became clinically apparent 1.5 and 6 years into stage IV disease. Genome profiling by SNP arrays revealed that HLA …

0301 basic medicineCancer ResearchT cellmedicine.medical_treatmentMedizinHuman leukocyte antigenCD8-Positive T-LymphocytesBiology03 medical and health sciencesAntigens NeoplasmmedicineHumansNeoplasm MetastasisMelanomaMelanomaCancerImmunosuppressionmedicine.diseasePhenotypeNeoplasm Proteins030104 developmental biologymedicine.anatomical_structureOncologyLatency stageImmunologyCD8Cancer Research
researchProduct

IL-17 promotes progression of cutaneous leishmaniasis in susceptible mice.

2009

Abstract Resistance to leishmaniasis in C57BL/6 mice depends on Th1/Tc1 cells. BALB/c mice preferentially develop Th2 immunity and succumb to infection. We now assessed the role of IL-17 in cutaneous leishmaniasis. During the course of Leishmania major infection, BALB/c CD4 cells and neutrophils produced increased amounts of IL-17 as compared with cells from C57BL/6 mice. This increase was associated with significantly increased IL-23 release from L. major-infected BALB/c dendritic cells (DC), whereas IL-6 and TGF-β1 production by BALB/c and C57BL/6 DC were comparable. Interestingly, lesion sizes in infected IL-17-deficient BALB/c mice were dramatically smaller and failed to progress as com…

NeutrophilsImmunologyLeishmaniasis CutaneousBiologyInterleukin-23ArticleLesionMiceImmune systemTh2 CellsCutaneous leishmaniasisSpecies SpecificityImmunitymedicineImmunology and AllergyAnimalsLeishmania majorGenetic Predisposition to DiseaseInterleukin 4Cells CulturedLeishmania majorMice KnockoutImmunity CellularMice Inbred BALB CInterleukin-17Cell DifferentiationDendritic Cellsmedicine.diseasebiology.organism_classificationUp-RegulationMice Inbred C57BLInterleukin 10ImmunologyDisease ProgressionInterleukin 17medicine.symptomJournal of immunology (Baltimore, Md. : 1950)
researchProduct